title: An increased ratio of interleukin-1 receptor antagonist to interleukin-1alpha in inflammatory skin diseases.
abstract: IL-1 receptor antagonist (IL-1ra) is a cytokine that competitively binds the IL-1 receptor to antagonize IL-1 activity without any agonist function. Previous experiments indicated that the ratio of IL-1ra to IL-1alpha in the normal stratum corneum (SC) was much higher in the sun-exposed face than in the sun-protected area, upper arms. It was also reported by another laboratory that IL-1ra is increased in the lesional skin of psoriatic patients. This study was designed to measure the contents of IL-1alpha and IL-1ra in non-lesional and pathological SC obtained from inflammatory skin diseases including psoriasis and non-psoriatic dermatoses such as atopic dermatitis. The SC materials were obtained with a non-invasive tape-stripping method. Their soluble fractions were prepared and assayed for IL-1alpha and IL-1ra by enzyme-linked immunosorbent assays. As a result we confirmed the previous findings that the ratio of IL-1ra to IL-1alpha in the normal SC was much higher in the face than in the sun-protected sites, the trunk as well as extremities. Next, we found that IL-1alpha contents were significantly reduced in the SC samples obtained from inflammatory skin regardless of whether their IL-1ra contents increased or unchanged. Moreover, we noted that an increased ratio of IL-1ra to IL-1alpha in the SC was not specific to psoriasis, but was also found in other inflammatory skin diseases including atopic dermatitis. This ratio was found to become lower after successful treatment of these skin lesions with topical glucocorticoids. We conclude from these observations that the increased ratio of IL-1ra to IL-1alpha in the SC is a non-specific phenomenon that can occur in any inflammatory skin diseases regardless of the inflammatory pattern, probably reflecting a skin regulation process against various kinds of inflammation.
authors.affiliation: Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan. terui@mail.cc.tohoku.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Terui
authors.forename: T
authors.initials: T
authors.lastname: Hirao
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Uesugi
authors.forename: M
authors.initials: M
authors.lastname: Honda
authors.forename: M
authors.initials: M
authors.lastname: Iguchi
authors.forename: N
authors.initials: N
authors.lastname: Matsumura
authors.forename: K
authors.initials: K
authors.lastname: Kudoh
authors.forename: S
authors.initials: S
authors.lastname: Aiba
authors.forename: H
authors.initials: H
authors.lastname: Tagami
mesh_terms: D003872:Dermatitis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D004817:Epidermis / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism*; D008297:Male; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*
chemical_list: D007375:Interleukin-1; D017472:Receptors, Interleukin-1